https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-omvohtm-mirikizumab-mrkz-first-class
0
0
FDA Approves Lilly's Omvoh™ (mirikizumab-mrkz), A First-in-Class Treatment for Adults with Moderately to Severely Active Ulcerative Colitis | Eli Lilly and Company - Investors | Eli Lilly and Company
10/26/23 at 3:25pm
Organization
Lilly.com
50 words
0
Comments
The Investor Relations website contains information about Eli Lilly and Company's business for stockholders, potential investors, and financial analysts.
You are the first to view
Create an account or login to join the discussion